Intellia Therapeutics, Inc. Financials

Market Capitalization $1.15 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-2.03
Forward PE	-2.05
Price to Sales TTM	$26.69
Price to Book MRQ	$1.19
Enterprise to Revenue	13.77
Enterprise to EBITDA	-1.13

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	0.00%
Operating Margin	-1588.96%
Return on Assets TTM	-27.81%
Return on Equity TTM	-52.23%

Income Statement

Revenue TTM	$43,086,000
Revenue per Share TTM	$0.45
Quarterly Revenue Growth	-24.00%
Gross Profit TTM	$-415,328,992
EBITDA	$-527,523,008
Net Income to Common TTM	$-522,284,000
Diluted EPS TTM	$-5.45
Quarterly Earnings Growth YoY	-24.02%

Balance Sheet

Total Cash MRQ	$658,113,984
Total Cash per Share MRQ	$6.46
Total Debt MRQ	$
Total Debt to Equity MRQ	10.56
Current Ratio MRQ	6.73
Book Value per Share MRQ	$9.46

Cash Flow

Operating Cash Flow TTM	$-356,739,008
Levered Free Cash Flow TTM	$-184,956,496

NTLA Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	101,849,000
Float Shares	100,567,317
Avg 10 Volume	3,759,640
Avg 30 Volume	None
Shares Short	21,668,143
Short Ratio	9.35
Short % of Shares	24.23%
% Held by Insiders	1.19%
% Held by Institutions	91.82%

Stock Price Summary

Beta	1.81
Fifty Two Week Low	$9.25
Fifty Two Week High	$34.87
Fifty Two Week Change	-138.22%
Day 50 MA	$13.11
Day 200 MA	$20.00

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date